Literature DB >> 12562701

Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections.

J Van Eldere1.   

Abstract

OBJECTIVES: To determine susceptibility rates and patterns in Pseudomonas aeruginosa strains isolated from nosocomial infections.
METHODS: Seven hundred and sixteen P. aeruginosa isolates from 40 different hospitals in Belgium and the Grand Duchy of Luxembourg were collected in 1999.
RESULTS: Resistance rates varied significantly between hospitals. Of the fluoroquinolones, ciprofloxacin showed least resistance (24%), levofloxacin showed 27.5% resistance and ofloxacin 37.5%. Of the aminoglycosides, amikacin was the most potent antibiotic (10.5% resistance), followed by isepamicin (12%), tobramycin (19.5%) and gentamicin (23.5%). Of the beta-lactam antibiotics, meropenem was the most active (9.5% resistance); piperacillin and piperacillin/tazobactam had, respectively, 24% and 17.5% resistance, ceftazidime 28.5%, cefepime 29.5%, ticarcillin/clavulanic acid 37% and aztreonam 55.5%. MIC distribution curves show the presence of significant subpopulations, with MICs just below breakpoint for many antibiotics.
CONCLUSION: Resistance of P. aeruginosa to penicillins, cephalosporins, fluoroquinolones and aminoglycosides varies between hospitals, but is increasing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12562701     DOI: 10.1093/jac/dkg102

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  26 in total

1.  The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.

Authors:  Hsun-Cheng Su; Kevin Ramkissoon; Janet Doolittle; Martha Clark; Jainab Khatun; Ashley Secrest; Matthew C Wolfgang; Morgan C Giddings
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

2.  Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.

Authors:  G L Drusano; Robert A Bonomo; Nadzeya Bahniuk; Juergen B Bulitta; Brian Vanscoy; Holland Defiglio; Steven Fikes; David Brown; Sarah M Drawz; Robert Kulawy; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

Review 3.  Aminoglycoside resistance in Pseudomonas aeruginosa.

Authors:  Keith Poole
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

4.  Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.

Authors:  Keith S Kaye; Zeina A Kanafani; Ashley E Dodds; John J Engemann; Stephen G Weber; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Maya Hites; Marjorie Beumier; Sabino Scolletta; Frédérique Jacobs
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

6.  Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.

Authors:  Didier Hocquet; Patrice Nordmann; Farid El Garch; Ludovic Cabanne; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 7.  Pharmacological considerations for the proper clinical use of aminoglycosides.

Authors:  Spyridon Pagkalis; Elpis Mantadakis; Michael N Mavros; Christina Ammari; Matthew E Falagas
Journal:  Drugs       Date:  2011-12-03       Impact factor: 9.546

8.  Increased susceptibility to pulmonary Pseudomonas infection in Splunc1 knockout mice.

Authors:  Yanyan Liu; Marissa E Di; Hong Wei Chu; Xinyu Liu; Ling Wang; Sally Wenzel; Y Peter Di
Journal:  J Immunol       Date:  2013-09-18       Impact factor: 5.422

9.  Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Herbert Spapen; Thierry Dugernier; Isabelle Delattre; Brice Layeux; Daniel De Backer; Xavier Wittebole; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-04-06       Impact factor: 9.097

10.  Incidence of multidrug-resistant organisms causing ventilator-associated pneumonia in a tertiary care hospital: a nine months' prospective study.

Authors:  Arindam Dey; Indira Bairy
Journal:  Ann Thorac Med       Date:  2007-04       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.